| Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab RD Mass, MF Press, S Anderson, MA Cobleigh, CL Vogel, N Dybdal, ... Clinical breast cancer 6 (3), 240-246, 2005 | 445 | 2005 |
| Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab CW Adams, DE Allison, K Flagella, L Presta, J Clarke, N Dybdal, ... Cancer Immunology, Immunotherapy 55, 717-727, 2006 | 412 | 2006 |
| Genetic absence of γ-interferon delays but does not prevent diabetes in NOD mice B Hultgren, X Huang, N Dybdal, TA Stewart Diabetes 45 (6), 812-817, 1996 | 312 | 1996 |
| Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin S Baumhueter, N Dybdal, C Kyle, LA Lasky | 301 | 1994 |
| A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet L Powell-Braxton, M Véniant, RD Latvala, KI Hirano, WB Won, J Ross, ... Nature medicine 4 (8), 934-938, 1998 | 280 | 1998 |
| Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies LL Sun, D Ellerman, M Mathieu, M Hristopoulos, X Chen, Y Li, X Yan, ... Science translational medicine 7 (287), 287ra70-287ra70, 2015 | 259 | 2015 |
| Overexpression of HER2/neu in solid tumours: an immunohistochemical survey HKW Koeppen, BD Wright, AD Burt, P Quirke, AM McNicol, NO Dybdal, ... Histopathology 38 (2), 96-104, 2001 | 226 | 2001 |
| Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women … N Dybdal, G Leiberman, S Anderson, B McCune, A Bajamonde, ... Breast cancer research and treatment 93, 3-11, 2005 | 221 | 2005 |
| Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability KA Poon, K Flagella, J Beyer, J Tibbitts, S Kaur, O Saad, JH Yi, S Girish, ... Toxicology and applied pharmacology 273 (2), 298-313, 2013 | 203 | 2013 |
| Diagnostic testing for pituitary pars intermedia dysfunction in horses NO Dybdal, KΜ Hargreaves, JE Madigan, DH Gribble, PC Kennedy, ... Journal of the American Veterinary Medical Association 204 (4), 627-632, 1994 | 198 | 1994 |
| Neurotrophin‐3 reverses experimental cisplatin‐induced peripheral sensory neuropathy WQ Gao, N Dybdal, N Shinsky, A Murnane, C Schmelzer, M Siegel, ... Annals of Neurology: Official Journal of the American Neurological …, 1995 | 179 | 1995 |
| Nitration and increased α‐synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction D McFarlane, N Dybdal, MT Donaldson, L Miller, AE Cribb Journal of neuroendocrinology 17 (2), 73-80, 2005 | 127 | 2005 |
| Sustained delivery of human growth hormone from a novel gel system: SABERTM FW Okumu, LN Dao, PJ Fielder, N Dybdal, D Brooks, S Sane, JL Cleland Biomaterials 23 (22), 4353-4358, 2002 | 113 | 2002 |
| Islet expression of interferon-α precedes diabetes in both the BB rat and streptozotocin-treated mice X Huang, B Hultgren, N Dybdal, TA Stewart Immunity 1 (6), 469-478, 1994 | 113 | 1994 |
| Hypertension and endothelial dysfunction in apolipoprotein E knockout mice R Yang, L Powell-Braxton, AK Ogaoawara, N Dybdal, S Bunting, ... Arteriosclerosis, thrombosis, and vascular biology 19 (11), 2762-2768, 1999 | 111 | 1999 |
| Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society DJ Leishman, TW Beck, N Dybdal, DJ Gallacher, BD Guth, M Holbrook, ... Journal of Pharmacological and Toxicological Methods 65 (3), 93-101, 2012 | 98 | 2012 |
| Equine Cushing’s disease: differential regulation of β-endorphin processing in tumors of the intermediate pituitary WR MILLINGTON, NO DYBDAL, R DAWSON JR, C MANZINI, ... Endocrinology 123 (3), 1598-1604, 1988 | 97 | 1988 |
| Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody K Staflin, CLZ de Zafra, LK Schutt, V Clark, F Zhong, M Hristopoulos, ... JCI insight 5 (7), 2020 | 74 | 2020 |
| Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice H Xiang, CB Nguyen, SK Kelley, N Dybdal, E Escandon Drug metabolism and disposition 32 (11), 1230-1238, 2004 | 72 | 2004 |
| Selective modulation of the expression of L-selectin ligands by an immune response D Hoke, RE Mebius, N Dybdal, D Dowbenko, P Gribling, C Kyle, ... Current Biology 5 (6), 670-678, 1995 | 72 | 1995 |
